KOSMOS: Improving Quality of Life in Nursing Home Residents: A Cluster Randomized Clinical Trial of Efficacy

Sponsor
University of Bergen (Other)
Overall Status
Completed
CT.gov ID
NCT02238652
Collaborator
The Research Council of Norway (Other), Rebekka Ege Hegemanns legat (Other), Helse Stavanger HF (Other), University of Oslo (Other), King's College London (Other), Karolinska Institutet (Other)
560
32
2
15
17.5
1.2

Study Details

Study Description

Brief Summary

Improving quality of life (QoL) in residents of nursing homes:

A cluster randomized clinical trial of efficacy - The KOSMOS study.

COSMOS (COmmunication (Advance Care Planning - ACP), Systematic pain assessment and treatment, Medication review, Occupational therapy, and Safety) is a practical intervention aimed to improve clinical and psychiatric challenges in NH patients. The COSMOS intervention combines the most effective research results to improve staff competence and patients' mental health, safety, QoL. We also aim to reduce psychotropic drug use and costs.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Communication
  • Behavioral: Systematic Pain Assessment and Treatment
  • Behavioral: Medication Review
  • Behavioral: Occupational therapy
  • Behavioral: Safety
N/A

Detailed Description

Background: Nursing home (NH) patients have complex mental health problems, disabilities and social needs, compounded by widespread prescription of psychotropic drugs. To preserve their dignity and quality of life is an important goal of our society. This can only be achieved within NHs that offer high competent conditions of treatment and care.

Research questions and hypotheses:
  1. Will the implementation of a communication and end-of-life decision making process have impact on interactions between patients, staff and family? We hypothesize that ACP will improve the interactions between patients, staff and family, and satisfaction in relatives and thereby improve the quality of life NH patients.

  2. Is the KOSMOS capable to affect agitation and aggression and reduce medication e.g. psychotropics in NH patient? We hypothesize that KOSMOS will significantly reduce agitation and aggression, the total amount of medication, and psychotropic drug use.

  3. What combination of interventions will give the broadest benefit, and could be delivered as a routine intervention as part of NH practice? We hypothesize that the comprehensive KOSMOS approach improves QoL and makes positive changes in NH practice.

  4. What other types of advantages are expected? We hypothesize that KOSMOS is a cost-effective approach, with potential to increase the safety and reduce mortality in NH patients.

Method: The KOSMOS intervention combines the most effective research results to improve staff competence, and patients' mental health, safety, QoL, and to reduce psychotropic drug use and costs. The efficacy testing of KOSMOS includes systematic literature review, a pilot study, a 9-month randomized control trial (RCT), and a dissemination plan. Data collection will take place at baseline, months 4, and 9. The intervention entails provision of staff training, study guidelines and manuals. NHs will be randomized to either KOSMOS or current best practice. We will include 38 NH long-term-care (LTC) wards (normally just one ward per NH) in Bergen, Stavanger, Oslo/Bærum, Sarpsborg and Sogn and Fjordane. In total 310 patients ≥65 years will be recruited from these wards

Primary and secondary outcome measures: Quality of life in late stage dementia (QUALID), QUALIDEM, EQ-5-D; Neuropsychiatric Inventory - NH edition (NPI-NH); Activities of Daily Living (ADL); Cornell; Mobilization - Observation - Behaviour - Intensity - Dementia 2 (MOBID-2); drug use; drug-related problems, START; STOP; cost-utility analysis (RUD-FOCA); hospital admission; and mortality, ActiWatch; Log registration of NH activities; Relatives satisfaction with conducted KOSMOS elements

Statistical analyses: include characteristics between 2 groups (Chi square, Mann-Whitney U), ANCOVA, ICC and p-values for each time-point and outcomes.

National and international collaboration: National collaboration between researchers at the Universities of Bergen, Oslo, and Stavanger is established. Internationally, colleagues from the EU COST-Action TD1005, Karolinska University, Stockholm and Kings College, London are engaged in this RCT.

Funding: The employment of two PhD-candidates (100%) and one post-doctoral fellow (50%) received funding by the Norwegian Research Council (Sponsor's Protocol Code: 222113) in 2012.

Study Design

Study Type:
Interventional
Actual Enrollment :
560 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Supportive Care
Official Title:
Improving Quality of Life in Nursing Home Residents: A Cluster Randomized Clinical Trial of Efficacy (The KOSMOS Study)
Study Start Date :
Aug 1, 2014
Actual Primary Completion Date :
Nov 1, 2015
Actual Study Completion Date :
Nov 1, 2015

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

Active Comparator: Intervention

Communication Systematic Pain Assessment and Treatment Medication Review Occupational therapy Safety

Behavioral: Communication
A preparation process before the patient become incapable of participating in life prolonging decisions
Other Names:
  • advance care planning
  • Behavioral: Systematic Pain Assessment and Treatment
    Assess pain with MOBID-2 Pain Scale and thereby improve pain management in dementia.
    Other Names:
  • MOBID-2
  • Behavioral: Medication Review
    An individual and systematic review of medication prescriptions to identify possible harmful drug effects and to reduce the use of psychotropic drugs.

    Behavioral: Occupational therapy
    Increase individual activities, based on function, personal interest and personality by educating the staff on these elements.

    Behavioral: Safety
    Focusing on developing a culture where staff has an active and constant awareness of how to prevent adverse events and a commitment to safety.
    Other Names:
  • patient safety
  • Outcome Measures

    Primary Outcome Measures

    1. Neuropsychiatric symptoms [9 months]

      Depression, anxiety an apathy will be assessed by the Neuropsychiatric Inventory - Nursing Home version (NPI-NH).

    2. Quality of life [9 months]

      Assessing quality of life by Qualidem, QUALID and EQ-5D.

    Secondary Outcome Measures

    1. Activities of daily living [9 months]

      Assessed by ADL index (range 0-18).

    2. Mood or depression [9 months]

      Assessed by Cornell Depression Scale (range 0-38)

    3. Pain [9 months]

      Assessed by Mobilisation-Observation-Behaviour-Intensity-Dementia (MOBID-2) Pain Scale (range 0-10)

    4. Medication review [9 months]

      Use of medication in number of people and dose, especially use of psychotropic drugs

    5. Drug-related problems [9 months]

      number of drug-drug-interactions using interactions database, number of drugs prescribed, number of anticholinergics prescribed, number of patients prescribed pain-medication with no pain on the MOBID-2 pain scale, number of patients with anti depressants with a low cornell depression rating scale in dementia.

    6. Admission to hospital and mortality [9 months]

      Questionnaire asking nurses wether the patient has been admitted to the hospital at month 4 and month 9.

    7. Cost-effectiveness [9 months]

      Resource use will be registered by Resource use in dementia - formal care (RUD-FOCA)

    8. Cost of medication [9 months]

      Cost-utility analysis will be performed

    9. Measure of activity [9 months]

      ActiWatch to register sleep and activity

    10. Nursing home activity [9 months]

      Log registration of NH activities

    11. Relatives satisfaction with conducted KOSMOS elements [9 months]

      Relatives satisfaction with conducted KOSMOS elements with questionary

    Other Outcome Measures

    1. Implementation indicators [9 months]

      Assessment of the quality of the implementation on each intervention by monthly visits and phone calls and review of the manuals.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Resident in long time care ward in Bergen, Bærum, Sarpsborg, Kvam, Fjell, Sund, Askøy and Øygarden
    Exclusion Criteria:
    • Dying patients with reduced consciousness at baseline

    • Active Schizophrenia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Solvik Baerum Akershus Norway 1304
    2 Donski Bo og behandlingssenter Baerum Akershus Norway 1346
    3 Mariehaven Bo og behandlingssenter Baerum Akershus Norway 1346
    4 Berger Bo og Behandlingssenter Baerum Akershus Norway 1349
    5 Kolaashjemmet Bo og Behandlingssenter Baerum Akershus Norway 1352
    6 Gullhaug Bo og behandlingssenter Baerum Akershus Norway 1354
    7 Osteraas Bo og behandlingssenter Baerum Akershus Norway 1361
    8 Solbakken Bo og Behandlingssenter Baerum Akershus Norway 1361
    9 Lønnås Bo og Rehabsenter Baerum Akershus Norway 1362
    10 Nordraaksvei bo og behandlingssenter Baerum Akershus Norway 1369
    11 Stabaekktunet Bo og behandlingssenter Baerum Akershus Norway 1369
    12 Stabekk Bo og Behandlingssenter Baerum Akershus Norway 1369
    13 Ask bo og omsorgssenter Askøy Norway
    14 Arna helseheim Bergen Norway
    15 Frieda Fasmers minne Bergen Norway
    16 Gullstøltunet Sykehjem Bergen Norway
    17 Hospitalet Betanien Bergen Norway
    18 Lyngbøtunet Bo og servicesenter Bergen Norway
    19 Slettebakken menighets eldresenter Bergen Norway
    20 University of Bergen Bergen Norway
    21 Strandebarmheimen Kvam Norway
    22 Toloheimen Kvam Norway
    23 Øysteseheimen Kvam Norway
    24 Borgen sykehjem Sarpsborg Norway
    25 Eplehagen bofellesskap Sarpsborg Norway
    26 Haugvoll sykehjem Sarpsborg Norway
    27 Helsehuset Sarpsborg Norway
    28 Kurland Sarpsborg Norway
    29 Tingvoll sykehjem Sarpsborg Norway
    30 Valaskjold omsorgssenter Sarpsborg Norway
    31 Sundheimen Sund Norway
    32 Tednebakkane omsorgssenter Øygarden Norway

    Sponsors and Collaborators

    • University of Bergen
    • The Research Council of Norway
    • Rebekka Ege Hegemanns legat
    • Helse Stavanger HF
    • University of Oslo
    • King's College London
    • Karolinska Institutet

    Investigators

    • Study Director: Bettina S. Husebø, MD, PhD, University of Bergen
    • Principal Investigator: Elisabeth Flo, PysD, PhD, University of Bergen
    • Principal Investigator: Irene Aasmul, Master, University of Bergen
    • Principal Investigator: Christine Gulla, MD, University of Bergen
    • Principal Investigator: Torstein Habiger, University of Bergen
    • Principal Investigator: Tony Elvegaard, University of Bergen

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Bettina Husebo, MD, assoc prof., University of Bergen
    ClinicalTrials.gov Identifier:
    NCT02238652
    Other Study ID Numbers:
    • 222113
    First Posted:
    Sep 12, 2014
    Last Update Posted:
    Apr 15, 2016
    Last Verified:
    Sep 1, 2014

    Study Results

    No Results Posted as of Apr 15, 2016